Inhaltszusammenfassung

The title compound ( systematic name: mu- oxo- bis{[ 4,15- bis( ethoxycarbonyl)- 5,14- dimethyl- 2,7,13,17- tetraazatricyclo- 16.4.0.0 (7,12)] docosa- 3,5,7,9,11,13,15,18( 1), 19,21- decaene- 2,17diido] iron( III)} sesquihydrate), [ Fe-2( C26H26N4O4) O] center dot 1.5H(2)O, crystallizes in the monoclinic space group C2/ c and has two iron centres which are coordinated by macrocyclic ligands with an N-4 donor set. These iron centres are bridged by a mu-oxo ligand, resulting in the formation of...The title compound ( systematic name: mu- oxo- bis{[ 4,15- bis( ethoxycarbonyl)- 5,14- dimethyl- 2,7,13,17- tetraazatricyclo- 16.4.0.0 (7,12)] docosa- 3,5,7,9,11,13,15,18( 1), 19,21- decaene- 2,17diido] iron( III)} sesquihydrate), [ Fe-2( C26H26N4O4) O] center dot 1.5H(2)O, crystallizes in the monoclinic space group C2/ c and has two iron centres which are coordinated by macrocyclic ligands with an N-4 donor set. These iron centres are bridged by a mu-oxo ligand, resulting in the formation of a dinuclear complex unit. The mu- oxo ligand interacts with a water molecule via strong hydrogen bonds. These solvent molecules aggregate by additional hydrogen bonds, producing a tetranuclear aggregate. Towards the outer rim of the cavity formed by the carboxyethyl substituents attached to the tetraaza- annulene systems there are additional solvent molecules. Due to much weaker hydrogen- bond interactions, the latter are disordered and have site- occupancy factors less than 1. » weiterlesen» einklappen

Autoren